Clinical trials: Skin Abnormalities
Atopic Dermatitis, Healthy
Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
In most recent years, the gut microbiome has been highlighted as a key player in the control of organs distant from the gut. Indeed, studies have raised evidence that gut microbiota exerts a control on various diseases including…
- Trial name
- NCT07017348
- Testing
- Clinical assessments, Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Dermatitis, Atopic
A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo
This study is a randomised, double-blind, placebo-controlled study to assess the efficacy of GW870086X cream formulation in subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT01299610
- Testing
- GW870086 2.0%, GW870086 0.2%, FP 0.05%
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
- Conditions
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency
- Trial name
- ENERGY (NCT05734196)
- Testing
- INZ-701
- Where
- 5 sites in United States, Spain and 1 more
- Volunteers
- 9 people
- Sponsor
- Inozyme Pharma
Atopic Dermatitis
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it improves AD and what the side effects are…
- Trial name
- NCT05117060
- Testing
- LEO 152020 tablet
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 216 people
- Sponsor
- JW Pharmaceutical
Skin Condition, Skin Diseases
VIO Imaging for Skin Tissue Assessment (VISTA)
To demonstrate the safety and effectiveness of the VIO device in obtaining in vivo images that show tissue features including epidermis, dermis, collagen, blood vessels, and/or pigment.
- Conditions
- Skin Condition, Skin Diseases, Skin Lesion, Skin Abnormalities
- Trial name
- VISTA (NCT05619471)
- Testing
- VIO Imaging
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Enspectra Health
Dermatitis, Atopic
Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis
The study shall explore whether treatment of atopic dermatitis is equally effective with Phoenix medical device as compared to standard therapy (Hydrocortisone cream).
- Trial name
- Phoenix (NCT01691209)
- Testing
- Phoenix (BAY81-2996), 1% Hydrocortison cream
- Where
- Germany
- Sponsor
- Bayer
Atopic Dermatitis
A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis
This is a multi-center, Phase 1b, double-blind, placebo-controlled, SAD and MAD, first-in-human study in subjects with mild to severe AD receiving si-544. The study consists of 2 parts, an SAD and an MAD part.
- Trial name
- NCT05383378
- Testing
- si-544
- Where
- 5 sites in Germany
- Volunteers
- 36 people
- Sponsor
- selectION Therapeutics GmbH
Skin Laxity, Lipodystrophy
CONFORM: Rotational Fractional Resection for Submental Contouring
This study will evaluate the safety and efficacy of rotational fractional resection (RFR) to improve neck contouring. RFR is used to remove loose skin and fat.
- Trial name
- NCT03407313
- Testing
- Rotational fractional resection (1.5mm diameter device)
- Where
- 6 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Recros Medica, Inc.
Atopic Dermatitis
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
- Trial name
- Measure Up 1 (NCT03569293)
- Testing
- Upadacitinib
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 912 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema.
- Trial name
- BROADEN2 (NCT07217015)
- Testing
- KT-621
- Where
- 61 sites in United States, Australia and 6 more
- Volunteers
- 200 people
- Sponsor
- Kymera Therapeutics, Inc.
Epidermolysis Bullosa
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
The purpose of this study was to assess whether the topical use of SD-101 cream (3% or 6%) was effective in treating wounds in participants with Simplex, Recessive Dystrophic, or Junctional non-Herlitz Epidermolysis Bullosa (EB).
- Trial name
- NCT02014376
- Testing
- SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Scioderm, Inc.
Atopic Dermatitis (AD)
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of…
- Trial name
- MG-K10 (NCT07103174)
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Skin Laxity
Post-Market Lower Eyelid Treatment With Renuvion in Greece
This is a prospective, multi-center, non-randomized, single-arm study of up to 15 subjects treated with the Renuvion APR System.
- Trial name
- NCT05605691
- Testing
- Renuvion APR System
- Where
- Greece
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Apyx Medical
Dermatitis, Atopic
A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis
The purpose of the study is to determine the impact of topical corticosteroids on the safety and effectiveness of Protopic Ointment in the short-term treatment of moderate to severe Atopic Dermatitis and to compare the safety and…
- Trial name
- NCT00106496
- Testing
- Protopic, Corticosteroid
- Where
- 24 sites in United States
- Volunteers
- 410 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28…
- Trial name
- NCT03000595
- Testing
- SAN007 Cream
- Sponsor
- Santalis Pharmaceuticals, Inc.
Menkes Disease
Copper Histidinate Treatment for Menkes Disease
This expanded access protocol provides subcutaneous copper histidinate for Menkes disease patients under 6 years of age.
- Trial name
- NCT04074512
- Testing
- copper histidinate
- Where
- 20 sites in United States
- Sponsor
- Sentynl Therapeutics, Inc.
Atopic Dermatitis, Eczema
Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)
The purpose of this research is to better understand how wrist-worn study devices that measure activity/motion ('accelerometry devices') can be used to assess scratching and sleep in participants aged 12-75 years, with and…
- Conditions
- Atopic Dermatitis, Eczema, Healthy
- Trial name
- ADAP (NCT05583019)
- Testing
- GENEActiv Accelerometry Device, Centrepoint Insights Watch (CPIW) Accelerometry Device, Apple Watch Accelerometry Device
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- SymmetryScience Group, Inc.
Atopic Dermatitis
Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
- Trial name
- NCT07150845
- Testing
- EVO756
- Where
- 29 sites in United States, New Zealand
- Volunteers
- 121 people
- Sponsor
- Evommune, Inc.
Atopic Dermatitis, Eczema
Using a Telemedicine Approach in a Genome-wide Association Study of Atopic Dermatitis - Searching for Novel Biomarkers in Clinically Relevant Phenotypes
Atopic eczema is a common skin disorder affecting at least 2-3% of the western population. Atopic eczema cannot be cured and therefore treatment aims to alleviate the symptoms of the disease.
- Conditions
- Atopic Dermatitis, Eczema, DNA
- Trial name
- NCT04965233
- Testing
- DNA reports, Information reports
- Where
- 2 sites in United States, Denmark
- Volunteers
- healthy volunteers welcome
- Sponsor
- Studies&Me
Allergy
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of QGE031 in Japanese atopic male subjects in order to determine the eligibility of Japanese patients in subsequent clinical…
- Trial name
- NCT01596712
- Testing
- QGE031
- Where
- Japan
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals